Empyrean Capital Partners LP Acquires Shares of 1,732,000 Kenvue Inc. $KVUE

Empyrean Capital Partners LP acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 1,732,000 shares of the company’s stock, valued at approximately $29,877,000. Empyrean Capital Partners LP owned approximately 0.09% of Kenvue at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in KVUE. Physician Wealth Advisors Inc. grew its holdings in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in Kenvue during the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. grew its holdings in Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after buying an additional 1,027 shares in the last quarter. Leonteq Securities AG purchased a new stake in Kenvue during the 4th quarter valued at approximately $45,000. Finally, DV Equities LLC purchased a new stake in Kenvue during the 4th quarter valued at approximately $46,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

KVUE has been the subject of a number of research analyst reports. Citigroup cut their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Barclays cut their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Argus upgraded Kenvue to a “hold” rating in a research report on Friday, March 6th. Canaccord Genuity Group increased their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. Finally, UBS Group lowered their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $19.33.

Insider Transactions at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.59% of the stock is currently owned by corporate insiders.

Kenvue Stock Down 2.2%

NYSE KVUE opened at $18.03 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The company has a market capitalization of $34.61 billion, a P/E ratio of 21.21, a P/E/G ratio of 1.40 and a beta of 0.54. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The stock has a 50 day moving average price of $17.49 and a 200-day moving average price of $17.56.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.24 EPS. As a group, equities analysts predict that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio is currently 97.65%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.